Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-07-2020 | Hepatocellular Carcinoma | Review – Cancer Research

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas

Authors: Sameer A. Dhayat, Zixuan Yang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2020

Abstract

Hepatocellular carcinoma (HCC) and pancreatic cancer (PC) belong to the most lethal malignancies worldwide. Despite advances in surgical techniques and perioperative multidisciplinary management, the prognosis of both carcinoma entities remains poor mainly because of rapid tumor progression and early dissemination with diagnosis in advanced tumor stages with poor sensitivity to current therapy regimens. Both highly heterogeneous visceral carcinomas exhibit unique somatic alterations, but share common driver genes and mutations as well. Recently, circulating tumor DNA (ctDNA) could be identified as a liquid biopsy tool with huge potential as non-invasive biomarker in early diagnosis and prognosis. CtDNA released from necrotic or apoptotic cells of primary tumors, metastasis, and circulating tumor cells can reveal genetic and epigenetic alterations with tumor-specific and individual mutation and methylation profiles. In this article, we focus on clinical impact of ctDNA as potential biomarker in patients with HCC and PC.

Adamo P et al (2017) Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget 8:87221–87233. https://doi.org/10.18632/oncotarget.20250 CrossRefPubMedPubMedCentral

Ako S et al (2017) Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology 17:285–290. https://doi.org/10.1016/j.pan.2016.12.011 CrossRefPubMed

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554. https://doi.org/10.1016/0092-8674(88)90571-5 CrossRefPubMed

An Y et al (2019) The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma Am J. Transl Res 11:6462–6474

Aucamp J, Bronkhorst AJ, Badenhorst CPS, Pretorius PJ (2018) The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev Camb Philos Soc 93:1649–1683. https://doi.org/10.1111/brv.12413 CrossRefPubMed

Bailey P et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52. https://doi.org/10.1038/nature16965 CrossRefPubMed

Bell RJ, Rube HT, Xavier-Magalhaes A, Costa BM, Mancini A, Song JS, Costello JF (2016) Understanding TERT promoter mutations: a common path to immortality. Mol Cancer Res 14:315–323. https://doi.org/10.1158/1541-7786.MCR-16-0003 CrossRefPubMedPubMedCentral

Berger AW et al (2018) Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget 9:2076–2085. https://doi.org/10.18632/oncotarget.23330 CrossRefPubMed

Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L (2001) Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A 98:6407–6411. https://doi.org/10.1073/pnas.101129998 CrossRefPubMedPubMedCentral

Bettegowda C et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra224. https://doi.org/10.1126/scitranslmed.3007094 CrossRef

Biankin AV et al (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399–405. https://doi.org/10.1038/nature11547 CrossRefPubMedPubMedCentral

Bolondi L et al (2013) Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis 45:712–723. https://doi.org/10.1016/j.dld.2013.01.012 CrossRefPubMed

Botezatu I et al (2000) Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46:1078–1084CrossRefPubMed

Bruhn N et al (2000) Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci 906:72–82. https://doi.org/10.1111/j.1749-6632.2000.tb06594.x CrossRefPubMed

Burris HA 3rd et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403 CrossRefPubMed

Cancer Genome Atlas Research Network (2017) Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169:1327–1341.e1323. https://doi.org/10.1016/j.cell.2017.05.046 CrossRef

Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, Lo YM (2008) Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54:1528–1536. https://doi.org/10.1373/clinchem.2008.104653 CrossRefPubMed

Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM (2010) K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 36:657–662. https://doi.org/10.1016/j.ejso.2010.05.014 CrossRefPubMed

Chen I et al (2017) Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 8:97769–97786. https://doi.org/10.18632/oncotarget.22080 CrossRefPubMedPubMedCentral

Cheng H et al (2017) Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Int J Cancer 140:2344–2350. https://doi.org/10.1002/ijc.30650 CrossRefPubMed

Chin V et al (2018) Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 3:CD011044. https://doi.org/10.1002/14651858.CD011044.pub2 CrossRefPubMed

Chiu RW et al (2008) Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 105:20458–20463. https://doi.org/10.1073/pnas.0810641105 CrossRefPubMedPubMedCentral

Cohen JD et al (2017) Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A 114:10202–10207. https://doi.org/10.1073/pnas.1704961114 CrossRefPubMedPubMedCentral

Collisson EA et al (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17:500–503. https://doi.org/10.1038/nm.2344 CrossRefPubMedPubMedCentral

Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923 CrossRefPubMed

Cui Y et al (2012) Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 18:6519–6530. https://doi.org/10.1158/1078-0432.CCR-12-0827 CrossRefPubMedPubMedCentral

Dabritz J, Preston R, Hanfler J, Oettle H (2009) Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19–9. Pancreas 38:534–541. https://doi.org/10.1097/MPA.0b013e31819f6376 CrossRefPubMed

Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, Xuezhi W (2002) A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19–9 analysis. Pancreas 25:336–341. https://doi.org/10.1097/00006676-200211000-00003 CrossRefPubMed

Diaz LA Jr, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579–586. https://doi.org/10.1200/JCO.2012.45.2011 CrossRefPubMedPubMedCentral

Diehl F et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990. https://doi.org/10.1038/nm.1789 CrossRefPubMed

Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22. https://doi.org/10.1038/nrc969 CrossRefPubMed

Earl J et al (2015) Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer 15:797. https://doi.org/10.1186/s12885-015-1779-7 CrossRefPubMedPubMedCentral

Eissa MAL et al (2019) Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenet 11:59. https://doi.org/10.1186/s13148-019-0650-0 CrossRef

El-Deiry WS et al (2019) The current state of molecular testing in the treatment of patients with solid tumors. CA Cancer J Clin 69:305–343. https://doi.org/10.3322/caac.21560 CrossRefPubMedPubMedCentral

Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775:181–232. https://doi.org/10.1016/j.bbcan.2006.10.001 CrossRefPubMed

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2 CrossRefPubMed

Gahan PB, Stroun M (2010) The virtosome-a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct 28:529–538. https://doi.org/10.1002/cbf.1690 CrossRefPubMed

Gamil M et al (2018) Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. J Med Virol 90:1080–1086. https://doi.org/10.1002/jmv.25026 CrossRefPubMed

Garcia-Olmo D, Garcia-Olmo DC, Ontanon J, Martinez E, Vallejo M (1999) Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol Histopathol 14:1159–1164. https://doi.org/10.14670/HH-14.1159 CrossRefPubMed

Groot VP et al (2019) Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res 25:4973–4984. https://doi.org/10.1158/1078-0432.CCR-19-0197 CrossRefPubMedPubMedCentral

Grutzmann R et al (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3:e3759. https://doi.org/10.1371/journal.pone.0003759 CrossRefPubMedPubMedCentral

Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K (2017) Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 49:635–642. https://doi.org/10.1038/ng.3805 CrossRefPubMedPubMedCentral

Hadano N et al (2016) Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer 115:59–65. https://doi.org/10.1038/bjc.2016.175 CrossRefPubMedPubMedCentral

Han LY et al (2014) Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci 11:164–171. https://doi.org/10.7150/ijms.6745 CrossRefPubMedPubMedCentral

He G, Chen Y, Zhu C, Zhou J, Xie X, Fei R, Wei L, Zhao H, Chen H, Zhang H (2019) Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma. Am J Transl Res 11(3):1428–1445PubMedPubMedCentral

Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61:112–123. https://doi.org/10.1373/clinchem.2014.222679 CrossRefPubMed

Henriksen SD et al (2016) Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Clin Epigenet 8:117. https://doi.org/10.1186/s13148-016-0286-2 CrossRef

Henriksen SD, Madsen PH, Larsen AC, Johansen MB, Pedersen IS, Krarup H, Thorlacius-Ussing O (2017a) Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma. Oncotarget 8:93942–93956. https://doi.org/10.18632/oncotarget.21397 CrossRefPubMedPubMedCentral

Henriksen SD, Madsen PH, Larsen AC, Johansen MB, Pedersen IS, Krarup H, Thorlacius-Ussing O (2017b) Promoter hypermethylation in plasma-derived cell-free DNA as a prognostic marker for pancreatic adenocarcinoma staging. Int J Cancer 141:2489–2497. https://doi.org/10.1002/ijc.31024 CrossRefPubMed

Hindson BJ et al (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83:8604–8610. https://doi.org/10.1021/ac202028g CrossRefPubMedPubMedCentral

Hu L, Chen G, Yu H, Qiu X (2010) Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 4:423–432. https://doi.org/10.1007/s12072-010-9164-8 CrossRefPubMedPubMedCentral

Hu Y et al (2018) False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res 24:4437–4443. https://doi.org/10.1158/1078-0432.CCR-18-0143 CrossRefPubMed

Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH (2011) Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol 91:702–707. https://doi.org/10.1016/j.yexmp.2011.08.004 CrossRefPubMed

Huang G et al (2014) Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 52:899–909. https://doi.org/10.1515/cclm-2013-0885 CrossRefPubMedPubMedCentral

Huang A et al (2016) Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital pcr is feasible and reflects intratumoral heterogeneity. J Cancer 7:1907–1914. https://doi.org/10.7150/jca.15823 CrossRefPubMedPubMedCentral

Huggett JF, Cowen S, Foy CA (2015) Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem 61:79–88. https://doi.org/10.1373/clinchem.2014.221366 CrossRefPubMed

Iizuka N et al (2011) Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta 412:152–158. https://doi.org/10.1016/j.cca.2010.09.028 CrossRefPubMed

Ikeda S, Lim JS, Kurzrock R (2018a) Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics. Mol Cancer Ther 17:1114–1122. https://doi.org/10.1158/1535-7163.MCT-17-0604 CrossRefPubMedPubMedCentral

Ikeda S et al (2018b) Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist 23:586–593. https://doi.org/10.1634/theoncologist.2017-0479 CrossRefPubMedPubMedCentral

Iyer P et al (2010) Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 88:107–111. https://doi.org/10.1016/j.yexmp.2009.09.012 CrossRefPubMed

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659–1665PubMed

Jaiswal S et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498. https://doi.org/10.1056/NEJMoa1408617 CrossRefPubMedPubMedCentral

Ji XF, Fan YC, Gao S, Yang Y, Zhang JJ, Wang K (2014) MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol 20:4723–4729. https://doi.org/10.3748/wjg.v20.i16.4723 CrossRefPubMedPubMedCentral

Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D (2007) K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34:55–62. https://doi.org/10.1097/01.mpa.0000246665.68869.d4 CrossRefPubMed

Jones S et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806. https://doi.org/10.1126/science.1164368 CrossRefPubMedPubMedCentral

Jung M, Klotzek S, Lewandowski M, Fleischhacker M, Jung K (2003) Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem 49:1028–1029CrossRefPubMed

Kanda M et al (2013) Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol 11(719–730):e715. https://doi.org/10.1016/j.cgh.2012.11.016 CrossRef

Karapetis CS et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765. https://doi.org/10.1056/NEJMoa0804385 CrossRefPubMed

Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R (2019) Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. Clin Cancer Res 25(20):6107–6118. https://doi.org/10.1158/1078-0432.CCR-18-3341 CrossRefPubMed

Kim MK et al (2018) Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma. Clin Chem 64:726–734. https://doi.org/10.1373/clinchem.2017.283721 CrossRefPubMed

Kimbi GC, Kew MC, Yu MC, Arakawa K, Hodkinson J (2005) 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20:1185–1190. https://doi.org/10.1111/j.1440-1746.2005.03951.x CrossRefPubMed

Kinugasa H et al (2015) Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 121:2271–2280. https://doi.org/10.1002/cncr.29364 CrossRefPubMed

Krantz BA, O'Reilly EM (2018) Biomarker-based therapy in pancreatic ductal adenocarcinoma: an emerging reality? Clin Cancer Res 24:2241–2250. https://doi.org/10.1158/1078-0432.CCR-16-3169 CrossRefPubMed

Kruger S et al (2018) Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol 29:2348–2355. https://doi.org/10.1093/annonc/mdy417 CrossRefPubMed

Van Laethem JL et al (2017) Phase I/II study of refametinib (BAY 86–9766) in combination with gemcitabine in advanced pancreatic cancer. Target Oncol 12:97–109. https://doi.org/10.1007/s11523-016-0469-y CrossRefPubMed

Leary RJ et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2:20ra14. https://doi.org/10.1126/scitranslmed.3000702 CrossRefPubMedPubMedCentral

Lee TH, Montalvo L, Chrebtow V, Busch MP (2001) Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41:276–282. https://doi.org/10.1046/j.1537-2995.2001.41020276.x CrossRefPubMed

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646–650PubMed

Liao PH, Chang YC, Huang MF, Tai KW, Chou MY (2000) Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol 36:272–276. https://doi.org/10.1016/s1368-8375(00),00005-1 CrossRefPubMed

Liao W et al (2016) Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 7:40481–40490. https://doi.org/10.18632/oncotarget.9629 CrossRefPubMedPubMedCentral

Liggett T et al (2010) Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116:1674–1680. https://doi.org/10.1002/cncr.24893 CrossRefPubMed

Lin SY et al (2011) A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J Mol Diagn 13:474–484. https://doi.org/10.1016/j.jmoldx.2011.05.005 CrossRefPubMedPubMedCentral

Lin M et al (2018) Circulating tumor DNA as a sensitive marker in patients undergoing irreversible electroporation for pancreatic cancer. Cell Physiol Biochem 47:1556–1564. https://doi.org/10.1159/000490874 CrossRefPubMed

Liu ZJ et al (2017) Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection. Neoplasma 64:795–802. https://doi.org/10.4149/neo_2017_519 CrossRefPubMed

Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390. https://doi.org/10.1056/NEJMoa0708857 CrossRefPubMed

Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350:485–487. https://doi.org/10.1016/S0140-6736(97)02174-0 CrossRefPubMed

Lo YM, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM (1998) Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 351:1329–1330. https://doi.org/10.1016/s0140-6736(05)79055-3 CrossRefPubMed

Madic J et al (2012) Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res 18:3934–3941. https://doi.org/10.1158/1078-0432.CCR-12-0309 CrossRefPubMed

Maire F et al (2002) Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 87:551–554. https://doi.org/10.1038/sj.bjc.6600475 CrossRefPubMedPubMedCentral

Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 142:241–243PubMed

Mansour LA, El Raziky M, Mohamed AA, Mahmoud EH, Hamdy S, El Sayed EH (2017) Circulating hypermethylated RASSF1A as a molecular biomarker for diagnosis of hepatocellular carcinoma. Asian Pac J Cancer Prev 18:1637–1643. https://doi.org/10.22034/APJCP.2017.18.6.1637 CrossRefPubMedPubMedCentral

Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54:1634–1637PubMed

Marchese R et al (2006) Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 32:171–177. https://doi.org/10.1097/01.mpa.0000202938.63084.e3 CrossRefPubMed

Marchio A et al (2018) Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin Exp Med 18:421–431. https://doi.org/10.1007/s10238-018-0502-9 CrossRefPubMed

Martinez P, McGranahan N, Birkbak NJ, Gerlinger M, Swanton C (2013) Computational optimisation of targeted DNA sequencing for cancer detection. Sci Rep 3:3309. https://doi.org/10.1038/srep03309 CrossRefPubMedPubMedCentral

Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson VV (2009) Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol 99:119–122. https://doi.org/10.1002/jso.21208 CrossRefPubMed

Melo SA et al (2015) Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:177–182. https://doi.org/10.1038/nature14581 CrossRefPubMedPubMedCentral

Melson J et al (2014) Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer. Int J Cancer 134:2656–2662. https://doi.org/10.1002/ijc.28593 CrossRefPubMed

Minchin RF, Carpenter D, Orr RJ (2001) Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. J Pharmacol Exp Ther 296:1006–1012PubMed

Moffitt RA et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47:1168–1178. https://doi.org/10.1038/ng.3398 CrossRefPubMedPubMedCentral

Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM (2012) Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol 13:111–115. https://doi.org/10.1016/j.ajg.2012.06.009 CrossRefPubMed

Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. https://doi.org/10.1200/JCO.2006.07.9525 CrossRefPubMed

Murtaza M et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112. https://doi.org/10.1038/nature12065 CrossRefPubMed

Nakano Y et al (2018) KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer 118:662–669. https://doi.org/10.1038/bjc.2017.479 CrossRefPubMedPubMedCentral

Nault JC, Villanueva A (2015) Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res 21:1786–1788. https://doi.org/10.1158/1078-0432.CCR-14-2602 CrossRefPubMed

Nault JC et al (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. https://doi.org/10.1038/ncomms3218 CrossRefPubMed

Oussalah A et al (2018) Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine 30:138–147. https://doi.org/10.1016/j.ebiom.2018.03.029 CrossRefPubMedPubMedCentral

Ozen C et al (2013) Genetics and epigenetics of liver cancer. N Biotechnol 30:381–384. https://doi.org/10.1016/j.nbt.2013.01.007 CrossRefPubMed

Park JK et al (2012) The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 41:95–101. https://doi.org/10.1097/MPA.0b013e318221c903 CrossRefPubMed

Park G et al (2018) Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients. Sci Rep 8:11631. https://doi.org/10.1038/s41598-018-30100-w CrossRefPubMedPubMedCentral

Patel H et al (2019) Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol 12:130. https://doi.org/10.1186/s13045-019-0824-4 CrossRefPubMedPubMedCentral

Perets R et al (2018) Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist 23:566–572. https://doi.org/10.1634/theoncologist.2017-0467 CrossRefPubMedPubMedCentral

Pietrasz D et al (2017) Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res 23:116–123. https://doi.org/10.1158/1078-0432.CCR-16-0806 CrossRefPubMed

Pishvaian MJ et al (2017) A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget 8:83446–83456. https://doi.org/10.18632/oncotarget.13225 CrossRefPubMed

Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013) Screening for pancreatic cancer: why, how, and who? Ann Surg 257:17–26. https://doi.org/10.1097/SLA.0b013e31825ffbfb CrossRefPubMed

Pratt ED, Cowan RW, Manning SL, Qiao E, Cameron H, Schradle K, Simeone DM, Zhen DB (2019) Multiplex enrichment and detection of rare KRAS mutations in liquid biopsy samples using digital droplet pre-amplification. Anal Chem 91(12):7516–7523. https://doi.org/10.1021/acs.analchem.8b01605 CrossRefPubMed

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155 CrossRefPubMed

Del Re M et al (2017) Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep 7:7931. https://doi.org/10.1038/s41598-017-08297-z CrossRefPubMedPubMedCentral

Reni M et al (2005) Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6:369–376. https://doi.org/10.1016/S1470-2045(05),70175-3 CrossRefPubMed

Rhim AD et al (2014) Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146:647–651. https://doi.org/10.1053/j.gastro.2013.12.007 CrossRefPubMed

Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R (2018) The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. Mol Cancer Ther 17:297–305. https://doi.org/10.1158/1535-7163.MCT-17-0360 CrossRefPubMed

Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:2140–2141. https://doi.org/10.1056/NEJMc1412266 CrossRefPubMed

Sausen M, Parpart S, Diaz LA Jr (2014) Circulating tumor DNA moves further into the spotlight. Genome Med 6:35. https://doi.org/10.1186/gm552 CrossRefPubMedPubMedCentral

Sausen M et al (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6:7686. https://doi.org/10.1038/ncomms8686 CrossRefPubMed

Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437. https://doi.org/10.1038/nrc3066 CrossRefPubMed

Semrad T et al (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518–524. https://doi.org/10.1007/s10147-014-0730-2 CrossRefPubMed

Shapiro B, Chakrabarty M, Cohn EM, Leon SA (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51:2116–2120. https://doi.org/10.1002/1097-0142(19830601)51:11%3c2116:aid-cncr2820511127%3e3.0.co;2-s CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551 CrossRefPubMed

Snyder TM, Khush KK, Valantine HA, Quake SR (2011) Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 108:6229–6234. https://doi.org/10.1073/pnas.1013924108 CrossRefPubMedPubMedCentral

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3:67–71

Stathopoulos GP et al (2006) A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587–592. https://doi.org/10.1038/sj.bjc.6603301 CrossRefPubMedPubMedCentral

Stigliano R, Burroughs AK (2005) Should we biopsy each liver mass suspicious for HCC before liver transplantation?—no, please don't. J Hepatol 43:563–568. https://doi.org/10.1016/j.jhep.2005.07.015 CrossRefPubMed

Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46:318–322. https://doi.org/10.1159/000226740 CrossRefPubMed

Sugimori M et al (2020) Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci 111:266–278. https://doi.org/10.1111/cas.14245 CrossRefPubMed

Sun FK et al (2013) Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig Dis Sci 58:1010–1015. https://doi.org/10.1007/s10620-012-2462-3 CrossRefPubMed

Sun K et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112:E5503–5512. https://doi.org/10.1073/pnas.1508736112 CrossRefPubMedPubMedCentral

Szymanska K et al (2004) Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia. West Africa Int J Cancer 110:374–379. https://doi.org/10.1002/ijc.20103 CrossRefPubMed

Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, Suzuki M, Furukawa E, Kato M, Hayashi H, Kohno T, Ueno H, Shimada K, Okusaka T, Nakagama H, Shibata T, Yachida S (2015) Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep 5:18425. https://doi.org/10.1038/srep18425 CrossRefPubMedPubMedCentral

Tamkovich SN, Cherepanova AV, Kolesnikova EV, Rykova EY, Pyshnyi DV, Vlassov VV, Laktionov PP (2006) Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci 1075:191–196. https://doi.org/10.1196/annals.1368.026 CrossRefPubMed

Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, Mutirangura A (2007) Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta 379:127–133. https://doi.org/10.1016/j.cca.2006.12.029 CrossRefPubMed

Tjensvoll K et al (2016) Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 10:635–643. https://doi.org/10.1016/j.molonc.2015.11.012 CrossRefPubMed

Uemura K, Hiyama E, Murakami Y, Kanehiro T, Ohge H, Sueda T, Yokoyama T (2003) Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep 10:277–283PubMed

Uemura T et al (2004) Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients. J Gastroenterol 39:56–60. https://doi.org/10.1007/s00535-003-1245-1 CrossRefPubMed

Von Hoff DD et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703. https://doi.org/10.1056/NEJMoa1304369 CrossRef

Villanueva A (2019) Hepatocellular Carcinoma. N Engl J Med 380:1450–1462. https://doi.org/10.1056/NEJMra1713263 CrossRefPubMed

Waddell N et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501. https://doi.org/10.1038/nature14169 CrossRefPubMedPubMedCentral

Wang J, Qin Y, Li B, Sun Z, Yang B (2006) Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 39:344–348. https://doi.org/10.1016/j.clinbiochem.2006.01.008 CrossRefPubMed

Watanabe F et al (2019) Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE 14:e0227366. https://doi.org/10.1371/journal.pone.0227366 CrossRefPubMedPubMedCentral

Wei T et al (2019) Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther 18:196–203. https://doi.org/10.1158/1535-7163.MCT-17-1298 CrossRefPubMed

Wen L et al (2015) Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res 25:1376. https://doi.org/10.1038/cr.2015.141 CrossRefPubMedPubMedCentral

Witkiewicz AK et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744. https://doi.org/10.1038/ncomms7744 CrossRefPubMed

Wong IH et al (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71–73PubMed

Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ (2000) Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6:3516–3521PubMed

Wong IH, Zhang J, Lai PB, Lau WY, Lo YM (2003) Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 9:1047–1052PubMed

Wu J et al (2014) Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases. Asian Pac J Cancer Prev 15:10647–10652. https://doi.org/10.7314/apjcp.2014.15.24.10647 CrossRefPubMed

Wu HC, Yang HI, Wang Q, Chen CJ, Santella RM (2017) Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis 38:1021–1028. https://doi.org/10.1093/carcin/bgx078 CrossRefPubMedPubMedCentral

Xiong Y, Xie CR, Zhang S, Chen J, Yin ZY (2019) Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res 11:5745–5756. https://doi.org/10.2147/CMAR.S197455 CrossRefPubMedPubMedCentral

Xu RH et al (2017) Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 16:1155–1161. https://doi.org/10.1038/nmat4997 CrossRefPubMed

Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ (2005) High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 25:266–272. https://doi.org/10.1111/j.1478-3231.2005.01084.x CrossRefPubMed

Yi JM et al (2013) Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res 19:6544–6555. https://doi.org/10.1158/1078-0432.CCR-12-3224 CrossRefPubMedPubMedCentral

Yoshida T, Yamashita Y, Kitano M (2019) Endoscopic ultrasound for early diagnosis of pancreatic cancer. Diagnostics (Basel). https://doi.org/10.3390/diagnostics9030081 CrossRef

Yu SC, Lee SW, Jiang P, Leung TY, Chan KC, Chiu RW, Lo YM (2013) High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem 59:1228–1237. https://doi.org/10.1373/clinchem.2013.203679 CrossRefPubMed

Yu J et al (2017) Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut 66:1677–1687. https://doi.org/10.1136/gutjnl-2015-311166 CrossRefPubMed

Zhang P et al (2013) Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChip. Hepatol Int 7:893–900. https://doi.org/10.1007/s12072-013-9437-0 CrossRefPubMed

Zhang BO et al (2015) Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Exp Ther Med 9:1383–1388. https://doi.org/10.3892/etm.2015.2221 CrossRefPubMedPubMedCentral

Zhang S et al (2018) Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study. Cancer Commun (Lond) 38:28. https://doi.org/10.1186/s40880-018-0303-2 CrossRef

Zill OA et al (2015) Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov 5:1040–1048. https://doi.org/10.1158/2159-8290.CD-15-0274 CrossRefPubMedPubMedCentral

Title: Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas
Authors: Sameer A. Dhayat
Zixuan Yang
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Pancreatic Cancer
Pancreatic Cancer
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03219-5

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2020

Older age and comorbidity in breast cancer: is RT alone the new therapeutic frontier?

Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies

Unilateral versus bilateral lymph-nodal metastases and oncologic outcome in vulvar cancer patients

A quick evaluation method of nosocomial infection risk for cancer hospitals during the COVID-19 pandemic

Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase–negative cells

Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage